PMID- 22694288
OWN - NLM
STAT- MEDLINE
DCOM- 20121113
LR  - 20181201
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 12
IP  - 8
DP  - 2012 Aug
TI  - Management of pegylated interferon alpha toxicity in adjuvant therapy of 
      melanoma.
PG  - 1087-99
LID - 10.1517/14712598.2012.694421 [doi]
AB  - INTRODUCTION: Both native IFNalpha2b and pegylated IFNalpha2b (PegIFNalpha2b) are approved 
      for the adjuvant treatment of high-risk melanoma. AREAS COVERED: This review 
      compares the toxicity profiles of high-dose IFNalpha2b (HDI) and PegIFNalpha2b, and 
      provides recommendations on the management of common PegIFNalpha2b-related 
      toxicities, based on available clinical data and published literature. EXPERT 
      OPINION: The toxicity profile of PegIFNalpha2b at the approved dose (6 mug/kg/week for 
      8 weeks then 3 mug/kg/week for up to 5 years) is qualitatively similar to HDI in 
      melanoma. The most common adverse events (AEs) are fatigue, anorexia, 
      hepatotoxicity, flu-like symptoms, injection site reactions and depression. 
      However, fatigue and flu-like symptoms appear less severe with PegIFNalpha2b, and 
      toxicity seems to occur earlier, whereas with HDI toxicity may increase with 
      time. Most AEs can be managed effectively by dose modification and aggressive 
      symptom control. Dosing to tolerance using a three-step dose reduction schedule 
      to maintain an ECOG performance status of 0 - 1 may enable patients experiencing 
      toxicity to remain on treatment; this can be applied readily in clinical 
      practice. PegIFNalpha2b is therefore a valuable alternative option for adjuvant 
      treatment in melanoma, with a toxicity profile similar to that of HDI overall but 
      a more convenient administration schedule.
FAU - Daud, Adil
AU  - Daud A
AD  - University of California, San Francisco, Melanoma Program, San Francisco 1600 
      Divisadero St, Rm A741, Box 1770, San Francisco, CA 94115, USA. 
      adaud@medicine.ucsf.edu
FAU - Soon, Christopher
AU  - Soon C
FAU - Dummer, Reinhard
AU  - Dummer R
FAU - Eggermont, Alexander M M
AU  - Eggermont AM
FAU - Hwu, Wen-Jen
AU  - Hwu WJ
FAU - Grob, Jean Jacques
AU  - Grob JJ
FAU - Garbe, Claus
AU  - Garbe C
FAU - Hauschild, Axel
AU  - Hauschild A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120614
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - G8RGG88B68 (peginterferon alfa-2b)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/*adverse effects
MH  - Chemotherapy, Adjuvant
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/administration & dosage/*adverse effects
MH  - Melanoma/*drug therapy
MH  - Polyethylene Glycols/administration & dosage/*adverse effects
MH  - Recombinant Proteins/administration & dosage/adverse effects
MH  - Skin Neoplasms/*drug therapy
MH  - Treatment Outcome
EDAT- 2012/06/15 06:00
MHDA- 2012/11/14 06:00
CRDT- 2012/06/15 06:00
PHST- 2012/06/15 06:00 [entrez]
PHST- 2012/06/15 06:00 [pubmed]
PHST- 2012/11/14 06:00 [medline]
AID - 10.1517/14712598.2012.694421 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2012 Aug;12(8):1087-99. doi: 10.1517/14712598.2012.694421. 
      Epub 2012 Jun 14.